Senior Medical Director, Therapeutic Area/Oncology
Jose Espinoza has more than 20 years of experience in drug development, which includes enrolling patients into cancer trials, helping design and execute studies, conducting medical monitoring and data analysis of global trials, interfacing with regulatory bodies and working with biotech and pharmaceutical companies to refine drug development strategies. He worked at Pivotal with key opinion leaders to develop new protocols for the treatment of hematological malignancies with CAR T-cells. He served as the global medical monitor (U.S./EU) in the pivotal Phase II study for the accelerated FDA approval of melflufen in relapsed/refractory multiple myeloma in February 2021. Dr. Espinoza holds a double specialization—clinical oncology (1992-1997) and clinical hematology and bone marrow transplantation (1997-2001)—and has more than 20 years of clinical experience as consultant onco-hematologist at public hospitals in Spain and Ireland. He joined Labcorp in October 2021.